Microbot Medical Enrolled the First Patient in its Pivotal Human Clinical Trial
08 Julio 2024 - 7:20AM
Microbot Medical Inc. (Nasdaq: MBOT) today announced the completion
of the first procedure in a patient utilizing its LIBERTY®
Endovascular Robotic Surgical System. The procedure took place at
Brigham and Women’s Hospital (BWH), a leading academic medical
center located in Boston, Massachusetts, as part of the Company’s
pivotal human clinical trial.
The clinical trial at BWH is led by Dr. Dmitry
Rabkin, MD, PhD, Assistant Chief, Division of Angiography &
Interventional Radiology, who also performed this first human case.
The trial is part of the Investigational Device Exemption (“IDE”)
for LIBERTY®, and the Company expects its results will support the
future submission to the FDA and subsequent commercialization.
“Enrolling the first patient in our pivotal
human clinical trial is a significant milestone for the Company,
and an important step on our journey to bring LIBERTY® to U.S.
physicians,” commented Juan Diaz-Cartelle, MD, Chief Medical
Officer of Microbot Medical. “We are very pleased with the rapid
pace of site activation, and I’m looking forward to enrolling
additional patients in the near future.”
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
clinical- stage medical device company that specializes in
transformational micro-robotic technologies, with the goals of
improving clinical outcomes for patients and increasing
accessibility through the natural and artificial lumens within the
human body.
The Investigational LIBERTY® Endovascular
Robotic Surgical System aims to improve the way surgical robotics
are being used in endovascular procedures today, by eliminating the
need for large, cumbersome, and expensive capital equipment, while
reducing radiation exposure and physician strain. The Company
believes the LIBERTY® Endovascular Robotic Surgical System’s remote
operation has the potential to be the first system to democratize
endovascular interventional procedures.
Further information about Microbot Medical is
available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating
results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions,
risks inherent in the development and/or commercialization of the
LIBERTY® Endovascular Robotic Surgical System, the outcome of its
studies to evaluate the LIBERTY® Endovascular Robotic Surgical
System, uncertainty in the results of pre-clinical and clinical
trials or regulatory pathways and regulatory approvals, including
whether the Company’s pivotal study in humans is successful, any
failure or inability to recruit physicians and clinicians to serve
as primary investigators to conduct regulatory studies which could
adversely affect or delay such studies, disruptions resulting from
new and ongoing hostilities between Israel and the Palestinians and
other neighboring countries, any lingering uncertainty resulting
from the COVID-19 pandemic, need and ability to obtain future
capital, and maintenance of intellectual property rights.
Additional information on risks facing Microbot Medical can be
found under the heading “Risk Factors” in Microbot Medical’s
periodic reports filed with the Securities and Exchange Commission
(SEC), which are available on the SEC’s web site at www.sec.gov.
Microbot Medical disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Contact:
Michal Efraty
IR@microbotmedical.com
Microbot Medical (NASDAQ:MBOT)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Microbot Medical (NASDAQ:MBOT)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024